Autism- Pipeline Review 2021

Autism is a neurological disorder that can cause significant communication, social, and behavioral challenges. Risk factors of this disorder includes family history, child's sex, Tourette syndrome, fragile X syndrome, and epilepsy. Various factors may affect the development of autism, and it is mainly developed by sensory sensitivities and medical issues such as seizures or sleep disorders, gastrointestinal (GI) disorders, as well as mental health challenges such as depression, anxiety, and attention issues. The symptoms of autism mainly appear by age 2 or 3. Some related symptoms may development even earlier, and often, it can be analyzed as early as 18 months. Treatment comprises antidepressants, SSRIs (selective serotonin reuptake inhibitors), antipsychotics, and sedatives.

According data published by Centers for Disease Control, in 2018 around 1 in 59 children is diagnosed with an autism spectrum disorder (ASD). Further, stated that, in America the cost of caring for patient infected with autism had reached US $268 billion in 2015 and would rise to US $461 billion by 2025 in the absence of more-effective interventions and support across the life span.

In 2019, Halifax Group participated in Chance Light Behavioral Health, Therapy & Education with an aim to conduct successful behavioral education and health solutions to many kids and young adults with an autism spectrum disorder.

Approximately 60% of pipeline drugs for Autism are in phase 2 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent Autism.

Report Description

The report on Autism- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Autism. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

• Assessment of pipeline products based on various stages of devolvement.
• Provides an overview of the global therapeutic landscape of Autism (Infectious Disease).
• Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
• The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
• Latest news, articles, press-release, and related conferences

• Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline